Cargando…
Development of targeted adjuvants for HIV-1 vaccines
Finding new adjuvants is an integrated component of the efforts in developing an effective HIV-1 vaccine. Compared with traditional adjuvants, a modern adjuvant in the context of HIV-1 prevention would elicit a durable and potent memory response from B cells, CD8(+) T cells, and NK cells but avoid o...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5594534/ https://www.ncbi.nlm.nih.gov/pubmed/28893282 http://dx.doi.org/10.1186/s12981-017-0165-8 |
_version_ | 1783263223351345152 |
---|---|
author | Liu, Jun Ostrowski, Mario |
author_facet | Liu, Jun Ostrowski, Mario |
author_sort | Liu, Jun |
collection | PubMed |
description | Finding new adjuvants is an integrated component of the efforts in developing an effective HIV-1 vaccine. Compared with traditional adjuvants, a modern adjuvant in the context of HIV-1 prevention would elicit a durable and potent memory response from B cells, CD8(+) T cells, and NK cells but avoid overstimulation of HIV-1 susceptible CD4(+) T cells, especially at genital and rectal mucosa, the main portals for HIV-1 transmission. We briefly review recent advances in the studies of such potential targeted adjuvants, focusing on three classes of molecules that we study: TNFSF molecules, TLRs agonists, and NODs agonists. |
format | Online Article Text |
id | pubmed-5594534 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-55945342017-09-14 Development of targeted adjuvants for HIV-1 vaccines Liu, Jun Ostrowski, Mario AIDS Res Ther Review Finding new adjuvants is an integrated component of the efforts in developing an effective HIV-1 vaccine. Compared with traditional adjuvants, a modern adjuvant in the context of HIV-1 prevention would elicit a durable and potent memory response from B cells, CD8(+) T cells, and NK cells but avoid overstimulation of HIV-1 susceptible CD4(+) T cells, especially at genital and rectal mucosa, the main portals for HIV-1 transmission. We briefly review recent advances in the studies of such potential targeted adjuvants, focusing on three classes of molecules that we study: TNFSF molecules, TLRs agonists, and NODs agonists. BioMed Central 2017-09-12 /pmc/articles/PMC5594534/ /pubmed/28893282 http://dx.doi.org/10.1186/s12981-017-0165-8 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Liu, Jun Ostrowski, Mario Development of targeted adjuvants for HIV-1 vaccines |
title | Development of targeted adjuvants for HIV-1 vaccines |
title_full | Development of targeted adjuvants for HIV-1 vaccines |
title_fullStr | Development of targeted adjuvants for HIV-1 vaccines |
title_full_unstemmed | Development of targeted adjuvants for HIV-1 vaccines |
title_short | Development of targeted adjuvants for HIV-1 vaccines |
title_sort | development of targeted adjuvants for hiv-1 vaccines |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5594534/ https://www.ncbi.nlm.nih.gov/pubmed/28893282 http://dx.doi.org/10.1186/s12981-017-0165-8 |
work_keys_str_mv | AT liujun developmentoftargetedadjuvantsforhiv1vaccines AT ostrowskimario developmentoftargetedadjuvantsforhiv1vaccines |